Trial Profile
A Multicenter, Open and Phase II Clinical Study of HX008 for the Treatment in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Pucotenlimab (Primary) ; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Taizhou Hanzhong Pharmaceuticals
- 21 Jan 2023 Results assessing clinical efficacy and biomarker analysis presented at the 2023 Gastrointestinal Cancers Symposium
- 25 Jul 2022 According to a Lepu Biopharma media release, based on results from this study the NMPA has approved Pucotenlimab conditionally to treat patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient advanced solid tumors Patients with advanced colorectal cancers have progressed following previous treatment with a fluoropyrimidine, oxaliplatin and irinotecan.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology